2. CareDx Inc. (NASDAQ:CDNA)
CareDx, Inc. is one of the more interesting biotech stocks for May 2026 because it sits in a specialized but important healthcare niche: transplant diagnostics and precision medicine. Based on the provided data, the stock was priced at $21.82, with an 11.16% 12-week price change, a forward P/E of 24.80, projected one-year EPS growth of 51.72%, and projected one-year sales growth of 19.80%. That combination gives CareDx both a growth profile and a clearer commercial identity than many biotech names.
CareDx describes itself as a precision medicine company focused on transplant patients and caregivers. Its integrated solutions include non-invasive molecular testing for heart, kidney, and lung transplants, laboratory products, digital health technologies, and patient solutions. This is important because transplant care is a lifelong process. Patients need monitoring, clinicians need reliable data, and healthcare systems need better tools to detect potential complications before they become severe. That gives CareDx a recurring and clinically relevant role in post-transplant care.
The company’s first-quarter 2026 results were strong. CareDx reported revenue of $118 million, up 39% year over year. Testing services revenue rose 48% to $91 million, while testing services volume increased 17% to about 54,900 tests. Patient and digital solutions revenue reached $16 million, representing 33% year-over-year growth. These are not small improvements. They show that CareDx’s core testing and digital solutions businesses are gaining traction.
The profitability shift is also worth noting. CareDx reported GAAP net income of $3 million, compared with a GAAP net loss of $10 million in the first quarter of 2025. Adjusted EBITDA improved to $19 million, compared with $5 million a year earlier. The company also generated $4 million in operating cash flow. This is an important change because biotech investors often reward companies that can move from losses toward operating leverage, especially when revenue growth remains strong.
CEO John W. Hanna said CareDx delivered another quarter of “record growth” driven by momentum in precision medicine testing services and patient and digital solutions. He also pointed to strategic steps such as advancing AlloHeme and agreeing to divest the Lab Products business to simplify the operating model and focus on expanding adjusted EBITDA margins. That is a serious business signal because CareDx is not just growing; it is also trying to streamline operations around higher-margin growth areas.
Another key development is the launch of VANTx, an AI-powered, cloud-native clinical data and analytics platform designed to convert complex transplant data into insights for clinical research and real-world evidence development. This adds an artificial intelligence and digital health angle to the CareDx story, which could help it appeal to investors looking for biotech stocks that also overlap with healthcare AI, data analytics, and precision medicine.
CareDx also raised its 2026 guidance. The company now expects full-year 2026 revenue between $447 million and $465 million, up from its prior guidance of $420 million to $444 million. It also raised adjusted EBITDA guidance to $43 million to $57 million. The company’s board also authorized a share repurchase program of up to $100 million over a period of up to 24 months, which may be interpreted by investors as a sign of confidence in the balance sheet and future cash generation.
For investors looking for transplant diagnostics stocks, precision medicine stocks, healthcare AI stocks, and biotech stocks with strong sales growth, CareDx has a very direct story. It is growing revenue, improving profitability, raising guidance, simplifying its business, and leaning into AI-powered transplant data analytics. The risk is that transplant testing volumes, reimbursement decisions, and payer behavior can still affect performance. But among the top biotech stocks to buy for May 2026, CareDx looks like one of the more balanced names for investors who want growth with improving operating discipline.
Click next to see the following stock...
